Vertex Pharmaceuticals Operating Income

Vertex Pharmaceuticals (VRTX) currently reports a operating income of $4.7B as of March 2026. That compares with $-740M in the prior-year period — up 738.4% year over year. Use the charts on this page to explore Vertex Pharmaceuticals's operating income history and peer comparisons.

Vertex Pharmaceuticals's operating income increased from $-740M to $4.7B — a 738.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vertex Pharmaceuticals reported $4.7B in operating income as of March 2026. That compares with $-740M in the prior-year period — up 738.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $4.7B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals, and consider following VRTX for alerts when major investors trade the stock.

Vertex Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $4.7B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRTX with unrelated industries.